Literature DB >> 22999323

Selection of high-risk patients for device intervention with the new advances in technology.

Arthur J Moss1.   

Abstract

The recent clinical therapeutic studies involving high-risk cardiac patients with genetic or acquired heart disease provide valuable insights into the potential for new advances in the technology for improving risk stratification to identify patients who can benefit from device therapy.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Year:  2012        PMID： 22999323      PMCID： PMC3505600          DOI： 10.1016/j.jelectrocard.2012.08.004

Source DB:  PubMed          Journal:  J Electrocardiol        ISSN： 0022-0736            Impact factor:   1.438


  11 in total

Review 1.  Long QT Syndrome.

Authors:  Arthur J Moss
Journal:  JAMA       Date:  2003 Apr 23-30       Impact factor: 56.272

2.  Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.

Authors:  Michael R Bristow; Leslie A Saxon; John Boehmer; Steven Krueger; David A Kass; Teresa De Marco; Peter Carson; Lorenzo DiCarlo; David DeMets; Bill G White; Dale W DeVries; Arthur M Feldman
Journal:  N Engl J Med       Date:  2004-05-20       Impact factor: 91.245

3.  Risk stratification for primary implantation of a cardioverter-defibrillator in patients with ischemic left ventricular dysfunction.

Authors:  Ilan Goldenberg; Anant K Vyas; W Jackson Hall; Arthur J Moss; Hongyue Wang; Hua He; Wojciech Zareba; Scott McNitt; Mark L Andrews
Journal:  J Am Coll Cardiol       Date:  2008-01-22       Impact factor: 24.094

4.  Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.

Authors:  Arthur J Moss; Wojciech Zareba; W Jackson Hall; Helmut Klein; David J Wilber; David S Cannom; James P Daubert; Steven L Higgins; Mary W Brown; Mark L Andrews
Journal:  N Engl J Med       Date:  2002-03-19       Impact factor: 91.245

5.  Mutations in cytoplasmic loops of the KCNQ1 channel and the risk of life-threatening events: implications for mutation-specific response to β-blocker therapy in type 1 long-QT syndrome.

Authors:  Alon Barsheshet; Ilan Goldenberg; Jin O-Uchi; Arthur J Moss; Christian Jons; Wataru Shimizu; Arthur A Wilde; Scott McNitt; Derick R Peterson; Wojciech Zareba; Jennifer L Robinson; Michael J Ackerman; Michael Cypress; Daniel A Gray; Nynke Hofman; Jorgen K Kanters; Elizabeth S Kaufman; Pyotr G Platonov; Ming Qi; Jeffrey A Towbin; G Michael Vincent; Coeli M Lopes
Journal:  Circulation       Date:  2012-03-28       Impact factor: 29.690

6.  A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators.

Authors:  A E Buxton; K L Lee; J D Fisher; M E Josephson; E N Prystowsky; G Hafley
Journal:  N Engl J Med       Date:  1999-12-16       Impact factor: 91.245

7.  Genotype-phenotype aspects of type 2 long QT syndrome.

Authors:  Wataru Shimizu; Arthur J Moss; Arthur A M Wilde; Jeffrey A Towbin; Michael J Ackerman; Craig T January; David J Tester; Wojciech Zareba; Jennifer L Robinson; Ming Qi; G Michael Vincent; Elizabeth S Kaufman; Nynke Hofman; Takashi Noda; Shiro Kamakura; Yoshihiro Miyamoto; Samit Shah; Vinit Amin; Ilan Goldenberg; Mark L Andrews; Scott McNitt
Journal:  J Am Coll Cardiol       Date:  2009-11-24       Impact factor: 24.094

Review 8.  Long QT syndrome.

Authors:  Ilan Goldenberg; Arthur J Moss
Journal:  J Am Coll Cardiol       Date:  2008-06-17       Impact factor: 24.094

9.  Cardiac-resynchronization therapy for the prevention of heart-failure events.

Authors:  Arthur J Moss; W Jackson Hall; David S Cannom; Helmut Klein; Mary W Brown; James P Daubert; N A Mark Estes; Elyse Foster; Henry Greenberg; Steven L Higgins; Marc A Pfeffer; Scott D Solomon; David Wilber; Wojciech Zareba
Journal:  N Engl J Med       Date:  2009-09-01       Impact factor: 91.245

10.  Genotype- and Sex-Specific QT-RR Relationship in the Type-1 Long-QT Syndrome.

Authors:  Jean-Philippe Couderc; Xiaojuan Xia; Isabelle Denjoy; Fabrice Extramiana; Pierre Maison-Blanche; Arthur J Moss; Wojciech Zareba; Coeli M Lopes
Journal:  J Am Heart Assoc       Date:  2012-04-24       Impact factor: 5.501
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.